Tag: alemtuzumab

EMA conducts safety review of alemtuzumab (Lemtrada)

Two recent scientific publications have reported on the long term safety and efficacy of Alemtuzumab (Lemtrada) for the treatment of relapsing-remitting MS

Study shows alemtuzumab can improve pre-existing disability in relapsing-remitting MS

Study shows that alemtuzumab is more effective than interferon in reducing disease activity in relapsing remitting MS